The LLS does not currently plan to reopen this program.
The grants must be translational in nature. Ideally, the applications will have a clinical trial proposed, or could lead to a clinical trial. Applications that are solely laboratory-based without consideration of using patient samples or future clinical testing will not be accepted for review.
Full details can be found at https://proposalcentral.altum.com/opportunities.asp?GMID=128
RFP Suggested Topics
- Clinical Trials: Examine the use of pharmaceuticals, nutraceuticals, or life-style changes as prevention of blood cancer onset, progression to full blown disease, or relapse. Applications could be for any premalignant conditions before the onset of blood cancer or after successful blood cancer therapy (i.e. prevention of relapse). Therapeutics could include small molecules, biologics, or immunotherapeutics.
- Biomarker evaluation: Develop and apply sensitive minimally invasive methods to detect precursor conditions before disease onset or sustained after successful therapy
- Use experimental systems to identify safe and effective therapeutic strategies to eliminate mutant clones early in disease stages or prevent recurrence of disease that could justify a clinical trial in prevention
- Drug the undruggable: Develop novel strategies to remove / deactivate tumor drivers that initiate, or predispose to, disease onset and/or develop novel approaches, such as synthetic lethality, to achieve the same goal.
How to Apply/Deadlines
RTFCCR uses proposalCENTRAL for Letter of Intent (LOI) and full application submission.
Letter of Intent – open
|June 1, 2017|
|Letter of Intent – close||October 1, 2017|
|Full Application – open||
November 1, 2017
|Full Application – close||
February 1, 2018
April 16, 2018
|Award Start Date||
July 1, 2018
For questions, please contact Eveline Mumenthaler, Director of RTFCCR (Eveline.email@example.com) or Lee Greenberger, Chief Scientific Officer of LLS (firstname.lastname@example.org)